Merck 1Q Net Soars Amid Fewer Charges

By Matt Egan Features FOXBusiness

Merck (MRK) weighed in with first-quarter results on Friday that beat the Street as the drug giant benefited from cost cutting and strength in its diabetes and asthma drugs.

Continue Reading Below

The Whitehouse Station, NJ-based blue-chip company said it earned $1.04 billion, or 34 cents a share, last quarter, compared with a profit of $299 million, or 9 cents a share, a year earlier.

Excluding one-time items, it earned 92 cents a share, surpassing consensus calls for 84 cents.
Merck, which is the No. 2 U.S. drug maker, said its sales grew 1.4% to $11.58 billion, exceeding forecasts for $11.37 billion.

“Our strong results were largely driven by double-digit growth of key products combined with deliberate cost control measures across all areas of the company as we continue to create a more effective and efficient operating model,” CEO Kenneth Frazier said in a statement.

A number of Merck’s key drugs reported sales increases, highlighted by a 14% jump in asthma drug Singulair’s sales to $1.33 billion and a 12% increase in sales of Remicade. Diabetes drug Januvia saw its revenue surge 45% to $739 million, while Vytorin’s sales inched up just 1% to $480 million.

More On This...

Merck upped the midpoint of its full-year earnings guidance, saying it now sees EPS of $3.66 to $3.76. Wall Street had been calling for EPS of $3.69.

Continue Reading Below

“It is clear that Merck's business momentum is building, and we continue to demonstrate the ongoing value of the merger,” Frazier said. “We're making progress in our robust late-stage pipeline, and leveraging the benefits of our expanded pharmaceutical and vaccine, animal health and consumer portfolio."

Shares of Merck gained 0.64% to $36.00 in Friday’s premarkets. The stock was off 1.1% year-to-date as of Thursday.